Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisi?q radiation.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4?,3?:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

Abstract: The present invention provides crystalline molecules and molecular complexes that comprise binding pockets of Sykcat and its homologues. The invention also provides crystals comprising the catalytic domain of Syk protein. The invention further provides a computer comprising a data storage medium encoded with the structure coordinates of Sykcat binding pockets and methods for using a computer to evaluate the ability of a chemical entity or compounds to bind to a crystalline molecule or molecular complex of the invention. This invention also provides methods of using the structure coordinates to solve the structure homologous proteins or protein complexes. The invention further provides methods of using the structure coordinates to screen for, design and optimize chemical entities or compounds, including inhibitory compounds, that bind to the catalytic domain of Syk or homologues thereof.

Abstract: Described is managing the changing of software implementations such as applications deployed to enterprise client users or machines. Precedence relationships between deployed applications are specified. To determine which applications to install for a given client, the precedence is applied to the subset of applications assigned or published to the client. At logon or machine reboot, an upgrade process evaluates the deployed applications and any upgrade relationships, setting applications for removal or installation. A user may also install an application that has been designated as optional. Also described is an application lifecycle model for replacing applications. For example, administrators can phase in upgrades as a pilot to a small group of users, roll out upgrades to a larger group, and then provide the application to all users. Upgrades may be mandatory or optional, and replaced programs may be removed and then replaced, or overlaid during installation.

Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Abstract: A drainable ostomy pouch having sidewalls of flexible sheet material defining a cavity therebetween and a downwardly-extending neck portion terminating in a discharge opening that is closed by folding the neck portion upwardly and opened by unfolding the neck portion downwardly. Each of the sidewalls of the neck portion is provided with a transversely-extending bias member that is formed of stiff but flexible, springlike plastic material. The bias members are normally flat so as to be in straight parallel closed condition but are openable under inwardly-directed finger pressure applied to their opposite ends to cause them to bow outwardly away from each other.

Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

Abstract: This invention provides compounds and methods for treating cancer. More particularly, the invention provides compounds that inhibit Chk-1. These compounds potentiate the action of DNA-damaging agents such as chemotherapy and radiation therapy.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Abstract: A method and system for managing and deploying applications across a computer network by assigning and publishing applications to user and computer policy recipients. Assigned applications are automatically applied via a script to the policy recipients, thereby ensuring that the recipient has an administrator-specified workstation configuration. Assigned applications are advertised so as to appear available to the user, by adding an application shortcut to the start menu, and by populating the machine registry with appropriate application information. Other applications may be published to users, whereby those applications are optionally available for use by users. Published application information is maintained in a centralized store of information on the network. Assigned and published applications may be installed on demand, such as when the application is activated.

Abstract: A water management system of the present invention provides a sunroof drain member formed as a continuous piece. The drain member supports a sunroof guide track, and removes water from the guide track and sunroof area. The sunroof guide track is secured to the drain member by a plurality of interlocking features. By forming the interlocking features as integral parts of the guide track and drain member this prevents leakage in weakening in the areas where fastening devices would otherwise need to be attached.

Abstract: A water management system of the present invention provides a sunroof drain member formed as a continuous piece. The drain member supports a sunroof guide track, and removes water from the guide track and sunroof area. The sunroof guide track is secured to the drain member by a plurality of interlocking features. By forming the interlocking features as integral parts of the guide track and drain member this prevents leakage in weakening in the areas where fastening devices would otherwise need to be attached.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) 1

Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.